Annals of Hematology

, Volume 85, Issue 9, pp 631–632 | Cite as

Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab

  • Dimitri FliegerEmail author
  • Sabine Hainke
  • Wolfgang Fischbach
Letter to the Editor


Vascular Endothelial Growth Factor Bevacizumab Oxaliplatin Pemetrexed Arteriovenous Malformation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Larson AM (2003) Liver disease in hereditary hemorrhagic telangiectasia. J Clin Gastroenterol 36:149–158PubMedCrossRefGoogle Scholar
  2. 2.
    Kindler HL, Karrison T, Lu C, Gandara DR, Stevenson J, Krug L, Janne P, Guterz TL, Stadler WM, Vokes EE (2005) A multicenter, double-blind, placebo-controlled randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo in patients (pts) with malignant mesothelioma (MM). Proc Am soc Clin Oncol 24:7019 (abstract)Google Scholar
  3. 3.
    Sadick H, Riedel F, Naim R, Goessler U, Hormann K, Hafner M, Lux A (2005) Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression. Haematologica 90:818–828PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Dimitri Flieger
    • 1
    • 2
    Email author
  • Sabine Hainke
    • 1
  • Wolfgang Fischbach
    • 1
  1. 1.Department of Internal Medicine IIKlinikum AschaffenburgAschaffenburgGermany
  2. 2.I. Medizinische KlinikGP-Klinikum RüsselsheimRüsselsheimGermany

Personalised recommendations